For example, only patients with class 1 BRAF-mutant melanomas respond to current targeted therapy agents, and acquired resistance invariably occurs, which may also confer cross-resistance to immunotherapy through MAPKi-driven phenotype switching/dedifferentiation (2, 3). The gene discussed is BRAF; the disease is melanoma.